Objective: To study the possible influences of amino acid (AA) intakes on growth and bone status in preterms.
Introduction
The aim of nutrition in preterm infants is to administer substrates from the first days of life in order to avoid or limit the period of early neonatal malnutrition and to achieve the rate of growth and body composition of a normal fetus of the same gestational age (GA). 1 Unfortunately, extremely preterm infants experience, during hospitalization, impaired growth and poor bone growth. [2] [3] [4] Growth and bone mineralization occur in particular in the third trimester of gestation; moreover, preterm infants are exposed to several risk factors, such as metabolic acidosis, diuretics, steroid administration and insufficient nutrient (protein, calcium, phosphorus, Vitamin D) intakes that could limit growth. 3, 5 Therefore, the administration of larger amounts of nutrients is considered a strategy to improve anabolism, and it has been established that amino acids (AAs) should be administered as soon as possible to avoid a catabolic state. 6, 7 The fetus in utero continuously receives AAs, but at birth the AA flow is suddenly interrupted, and the stress of delivery, alongside that deriving from potential infections and handling procedures, can lead to an increased protein catabolism.
A protein intake of 1.5 g kg À1 per day is recommended for the preterm infant in order to prevent the breakdown of endogenous tissue 8 but the requirements of the growing fetus from gestational weeks 24 to 32 are between 3.5 and 4.0 g kg À1 per day, 9 although AA supplementation in the first days often does not reach these values. It has been demonstrated that early AA administration improves protein 10 and albumin synthesis, 11 and that early supplementation of AAs is associated with better outcome 12 and better growth 13, 14 even after hospital discharge. 15 Nonetheless, most of the randomized studies considered only limited AA intakes soon after birth 6, 7, 16 and, to our knowledge, there are no studies that analyze bone growth with different AA regimens.
The objective of our study was to verify, in a group of preterm infants weighing <1250 g, whether a higher compared with a lower parenteral AA intake improves growth and bone status without signs of AA intolerance.
Methods
Premature infants, hospitalized from May 2009 to December 2010 in the neonatal intensive care unit at the Department of Pediatrics of the University Hospital of Padova (Italy), were randomly assigned to receive standard (3 g kg À1 per day; group S) or higher (4 g kg À1 per day; group H) AA intake during the entire period of parenteral nutrition support.
Inclusion criteria were birth weight <1250 g and the presence of a central venous line. Patients were excluded if they were >72 h of age, had congenital infection, a major congenital anomaly or metabolic disorders. All decisions to adjust the clinical support of the infants were made by their primary physicians, who were blinded to AA intake. The study was approved by the local Ethical Committee and informed consent was obtained from parents before the study.
Before enrollment, all patients received an intravenous infusion of glucose and 1-1.5 g kg À1 per day of AAs, provided as TrophAmine 6% (Baxter, Rome, Italy) from birth in accordance with our neonatal intensive care unit practice.
All patients received a progressive parenteral nutrition regimen with the same non-proteic energy intake and a different AA intake. For group S, AA supplementation was started at 1.5 g kg À1 per day and advanced from 0.5 g kg À1 per day to a maximum of 3 g kg
À1
per day on day 4 of the study. For group H, AA supplementation started at 2 g kg À1 per day and advanced from 1 g kg À1 per day to a maximum of 4 g kg À1 per day on day 4 of the study. Calcium and phosphorus intakes were between 1 and 2 mmol kg À1 per day to keep serum calcium between 2 and 2.5 mmol l À1 and serum phosphorus between 1.8 and 2.6 mmol l À1 . Parenteral vitamin D administration was 30 UI kg À1 per day. As feeding advanced, intravenous fluids were decreased accordingly to keep total fluids below 150 ml kg À1 per day in the first month. Minimal enteral feeding (10-20 ml kg À1 per day) 17 was started on the second day of life, either with preterm formula or with mother's own milk. After day 7, feedings were advanced at a rate of 10-20 ml kg À1 per day. When an intake of 100 ml kg
per day was reached, human milk was fortified (FM 85, Nestlé, Italian SPA, Milan, Italy), starting with 1 g to 4 g per 100 ml of human milk. With the advancement of enteral feeding, we decreased parenteral AA supplementation to 1 g kg À1 per day in the S group and 1.5-2 g kg À1 per day in the H group, respectively. For both groups, parenteral AA supplementation was stopped when feedings reached >100-120 ml kg À1 per day and the patient was considered to have completed the study.
Human milk has been estimated to contain 1.2 g protein per 100 ml and 70 Kcal per 100 ml, 18 and 0.2 g of protein and 3.53 Kcal were added to human milk for every g of fortifier.
The preterm formula had a protein content of 2.03 g per 100 ml.
Before study start, on day 3, day 7 and once a week during parenteral nutrition, blood samples were drawn to determine biochemical parameters such as urea and base excess (BE; to assess protein tolerance), protidemia, electrolytes, calcium, phosphorus, magnesium, alkaline phosphatase (ALP), and creatinine. We monitored glycemia every morning during parenteral nutrition and at least 3 times a day during the first week of parenteral nutrition. Episodes of hyperglycemia (glycemia >150 mg dl À1 in two examinations performed 4 h apart), 19 and daily diuresis were also recorded at least during the parenteral nutrition administration.
Growth was assessed through anthropometric measures. We logged daily weight, weekly total length and head circumference from birth to discharge and through hospitalization, and growth parameters like maximum weight decrement, days to regain birth weight and days to reach 1800 g.
In a subgroup of patients (37) , lower limb length (LLL) was measured weekly during the first month of life and at 36 weeks of GA, using a neonatal knemometer (Digital-TaschenMessschieber, Messwelt, Hagen, Germany). We measured the limb length with the infant lying in the supine position, with 901 flexion at the hip and knee. We collected three readings for each measure and the result was expressed as the mean of these readings. In vitro precision was calculated by making 30 measurements on a 100 mm perspex rod, which gave a mean (s.d.) length of 99.99 (0.06) mm. 20 Quantitative ultrasound (QUS) was performed with DBM Sonic BONE PROFILER (IGEA, Carpi, Modena, Italy) to assess bone status at birth, at 21 days of life and at 36 weeks of GA. QUS is a safe, X-ray-free technique, is bedside disposable and does not require sedation or immobilization. The device uses an emitting (producing 1.25 MHz pulses) and a receiving probe; the acoustic coupling with the skin is provided by warm gel. The device measures the distance between the probes and the time elapsing between emission and reception to calculate the speed of sound, that is the velocity of the ultrasound pulse through the site of measurement. 21 To evaluate density and bone structure, we tested the second metacarpus bone transmission time (mcBTT, in ms), calculated as the difference between the arrival time at the receiving probe of the fastest ultrasound pulse, traveling through bone tissue, and the arrival time of the ultrasound pulse traveling through soft tissue only. The mcBTT value depends on the thickness and mineralization of the cortical bone, and it has been demonstrated that its value is independent from the amount of soft tissue surrounding bone. 21 The sensibility was 0.01 mm for distance and 0.05 ms for speed with a tolerated range of 10 m s À1 ; standard error for repeated measures was 0.03 ms for mcBTT. The device provides mcBTT s.d. score using published growth charts for preterm infants. 21 All physicians performing QUS and collecting anthropometric measures were blinded to the group of the examined infants.
Clinical outcome was also recorded: death, hospitalization period, parenteral nutrition period, days at full enteral feeding, postnatal use of steroids, proven necrotizing enterocolitis (defined as Bell stage II or III), severe intracranial hemorrhage (grade III or IV using the Papile classification), incidence of periventricular leukomalacia and bronchopulmonary dysplasia (defined as supplemental oxygen required at 36 weeks after conception), severe retinopathy of prematurity (grade X3) and proven sepsis (deterioration of clinical condition with positive blood culture).
Data were expressed as individual values or mean ± s.d. and compared by unpaired t-test. We analyzed data using SPSS 13.0 (IBM, Armonk, New York, USA) and Microsoft Excel 2010 for the statistical analysis. Pearson's correlation was used to analyze the relationships between variables. Categorical variables were compared using contingency tables. Significance was set at P<0.05.
Results
From May 2009 to December 2010, 159 patients were hospitalized in our neonatal intensive care unit. Of these, 136 patients were enrolled in the study; 21 were either considered too unstable to continue the study protocol by the attending neonatologist or were discharged to other hospitals (13 for group S and 8 for group H). In all, 55 patients for group S and 60 for group H completed the study.
In the study population, mean GA was 27.70±1.99 weeks (min 23.0, max 32) and mean birth weight was 935.87 ± 204.08 g (min 500 g, max 1245 g). Also, 16% of preterm infants were small for gestational age (16.3% in group S, 13.3% for group H; P ¼ 0.79).
Differences in clinical conditions (Apgar at 5 min, CRIB (clinical risk index for babies)) and anthropometry (birth weight, total length, head circumference and LLL) at birth were not detected as well as in ultrasound parameters (Table 1 ). There were no differences in fluid intakes and non-proteic calories during the study period, although as expected, total protein intakes and parenteral protein intakes were different between groups (Table 2) .
Higher levels of urea were found in group H (Table 2) ; on day 21, these data reached significance. Nonetheless, BE, creatinine and urine output were not different between groups during the study period ( Table 2 ). The frequency of hyperglycemia was similar between groups (data not shown). Levels of ALP were significantly higher in group H at 7 days of life but there were no differences at 21 days of life (Table 2) . No other differences were found in the other biochemical parameters recorded during the study (data not shown).
The rate of growth in the first weeks of life was higher in group H compared with group S and, in particular, reached significance in the third week of life (P<0.01; Table 3 ). Days to reach 1800 g were less in the H group compared with the S group (58.79±20.02 vs 51.69 ± 16.09 days) and these data were close to significance (P ¼ 0.052). Other anthropometric parameters (maximum weight decrement, days to regain birth weight) of the two groups are reported in Table 3 . There were also significant differences in medium-term anthropometric measures: weight and length at 36 weeks of GA (respectively Pp0.01 and P ¼ 0.02; Table 3 ). Weight at 36 weeks of GA was significantly correlated with total AA administration in the first and second weeks of life (R ¼ 0.35, P<0.01; R ¼ 0.33, P<0.01 respectively).
Evaluating bone status, we did not observe in the two groups different values of mcBTT at 3 weeks of life and 36 weeks of GA (Table 3) . We found a decrease in mcBTT measure at 3 weeks of life compared with basal measure (mcBTT 3rd week-mcBTT basal, P ¼ 0.04) in the H group. We found an inverse correlation between mcBTT at 21 days and protein intake at 3 weeks (r ¼ À0.39; P<0.01), whereas mean non-proteic energy and total energy were positively correlated (Table 4) . There was also a positive correlation between mcBTT at 21 days and mean BE of the first week (Table 4) .
We did not find differences between groups in bone status at 36 weeks of GA (Table 3) . Nonetheless, we detected significant and Parenteral amino acid intakes: growth and bone status S Scattolin et al positive correlations between mcBTT at 36 weeks of GA and nutritional intakes such as energy and AA intakes in the first weeks of life (Table 4) . We found a positive correlation between mcBTT at 21 days and 36 weeks of GA and growth parameters (Table 4 ). In particular, a correlation was found between mcBTT and LLL at 21 days (R ¼ 0.56, P<0.01). No differences were detected in clinical outcome as shown in Table 5 .
Discussion
Preterm infants who do not receive an appropriate AA intake lose daily >1-2% of their protein stores; 22 nonetheless, the introduction of AAs in the first days of life has been limited because of the fear of higher urea levels and metabolic acidosis.
We found higher levels of blood urea in group H, but the levels were always within the range of normality of a fetus of the same GA. 23 Moreover, blood pH and creatinine and urine output were not different between groups during the study period. In our study, as previously reported, 24, 25 we used urea and metabolic acidosis levels as indexes of protein toxicity. Some authors have reported changes in urea plasma levels with parenteral AA supplementation, 24, 26 whereas others have not found it. 16, 25, 27 Nonetheless, higher urea levels may not be a reliable marker for protein intolerance but may reflect an appropriate utilization of AAs. Urea is a by-product of AA oxidation and the human fetus is able to synthesize it during gestation by means of an appreciable enzymatic activity that exceeds that of term newborns and adults, 28 when AAs can be used not only for accretion but also as an energy source. As in other studies, our results did not find differences in the level of metabolic acidosis 6, 16, 24, 25, 29 during parenteral AA administration and, in our population, blood pH lay within the range normally observed in preterm infants.
Studies comparing lower and higher intravenous AA intakes 15, 24 highlighted differences in growth advantages. Higher AA amount (3.5 g kg À1 per day) did not improve growth in a group of 122 Abbreviations: BE, base excess; GA, gestational age; i.v., intravenous; mcBTT, metacarpus bone transmission time; NPE, non-proteic energy.
Bold values emphasize statistically significant data. Abbreviations: Group H, group of patients receiving higher amino acid intakes; Group S, group of patients receiving standard amino acid intakes.
Parenteral amino acid intakes: growth and bone status S Scattolin et al newborns. 26 In addition, higher intakes resulted in excess levels of some AAs, raising concern about the impact of those plasma AAs levels on important health outcomes (liver injury, growth and neurodevelopment). Porcelli et al. 24 did not find differences in growth in preterm infants receiving higher or lower AA intakes, but did find that corrected parenteral AA intakes at postnatal week 1 correlated directly with weight gain from birth to postnatal week 2. 24 Furthermore, in a retrospective review, Olsen et al. 14 found that the addition of 1 g of protein per kg per day could increase weight growth of B4 g kg À1 per day. It has also been reported that infants who received X3 g kg À1 per day of parenteral AAs within the first 5 days of life increased anthropometric parameters at 36 weeks of GA (better weight, length and head circumference), and fewer infants in the same group were found with head circumference below the 10th and 5th percentiles at the 18-month follow-up visit. 15 Early higher protein intakes (20% greater) in a group of extremely low birth weight infants compared with an historical control group were associated with improved weight and length growth outcomes at discharge. 25 In our population, there were significant differences between anthropometric parameters and, in particular growth in the first weeks, weight and length at 36 weeks of GA. However, we have to point out that our study intervention lasted only so long as parenteral nutrition was being administered, so that other confounding factors could have contributed to better growth in the H group after this period. Moreover, the S group had a higher, although not significant, number of small for gestational age infants. Nonetheless, protein intakes in the first and second weeks of life positively correlated with weight at 36 weeks of GA, thus suggesting a possible influence of early AA intakes on growth.
However, the major limitation of our study is that we did not investigate yet long-term neurological outcome. Nonetheless, as previously reported, no adverse effect was reported on neurodevelopmental outcome in a group of infants who received higher AA intakes in the first 5 days of life, 15 and early intakes of AAs were found to correlate with Bayley scale scores at 18 months; each g kg À1 per day of protein intake was associated with an 8.2 point increase in the Motor Development Index. 30 Nonetheless, in a very recent study, newborns receiving higher intravenous AAs (up to 4 g kg À1 per day) did not improve global growth at 2 years and had temporarily lower Motor Development Index score at 18 months. Interestingly, cumulative concentrations of AAs negatively correlated with Motor Development Index at 18 months (R ¼ 0.44, P ¼ 0.008). 31 Anyway, how much protein is too much still has to be determined as no consensus exists for a normative AA profile. Neonatal AA concentrations had been compared with those of second-and third-trimester human fetuses in which cordocentesis was performed 32 or using samples obtained in normal newborns after birth. 26 We know that higher AA intakes result in higher AA levels, 31 but we still do not have a sensitive and reliable marker of AA toxicity readily available at the bedside. We think that future research, including plasma AAs concentrations and isotope tracer techniques, are needed to further understand AA metabolism and to correlate it to short-and long-term postnatal growth and neurodevelopmental outcome. In our study, patients receiving higher AA intakes had a significant decrease in mcBTT at day 21. Although BE was not significantly different in newborns receiving higher AA intakes, mcBTT at 3 weeks positively correlated with mean BE in the first week, suggesting that acidosis may have a role in the developing bone. Acidosis increased renal calcium and phosphorus excretion in a group of mild preterm infants 33 and, as already reported in adults, increased urinary calcium excretion may be caused by physicochemical dissolution with net alkali release from bone. However, as we have already reported, no clinical associations between protein intake and degree of acidosis was previously found, 25, 27 and in a recent study the net daily effect of protein administered (g kg À1 ) on bicarbonate level was À0.9 mmol l À1 and it was considered clinically insignificant. 34 We think that the proceeding of this study analyzing the possible relation of AA intakes, urinary calcium excretion and bone status could help us to clarify this point. However, nutritional intakes such as energy and AA intakes in the first weeks were positively correlated with mcBTT at 36 weeks of GA. This is an interesting result as studies on total parenteral nutrition and bone growth had been reported 35 but, to our knowledge, no studies on protein intakes and bone status have yet been published. Weiler et al. 36 showed that in preterm infants, early aggressive nutrition support with minimal enteral feeding enhances bone mineral content, although they did not find specific correlations with AA or total energy intakes. Our findings confirm that a balanced supply of energy and proteins, alongside with calcium, phosphorus and vitamins, is a necessary prerequisite for normal bone development as mineralization occurs when minerals are incorporated into organic bone matrix after its synthesis and deposition by osteoblasts. 5 In our population, we did not find correlations between bone status and ALP. Other studies found that QUS measurements inversely correlated with ALP 37 and bone status was significantly worse in infants with ALP >900 U l À1 . 2 In another study, infants with a combination of high ALP (>850 U l
À1
) and low phosphate (<1.2 mmol l À1 ) 35 had the lowest absolute QUS measurements of any infants but the same author questions the role of ALP as a screening test for osteopenia. ALP in fact is the sum of liver, intestine and bone isoforms, and other confounding factors could have contributed to the lack of correlation between mcBTT and ALP in our study population.
Of the considered anthropometric parameters, LLL was the one that best correlated to bone status (mcBTT). LLL has been correlated to bone status at birth but not in the postnatal period. 38 If this preliminary result will be confirmed in a larger number of patients, LLL could thus be a useful and simple marker of the developing bone status.
Conclusion
Our study suggests that early higher AA intakes result in short-term growth advantages without signs of intolerance in the short period. Nutritional intakes could influence bone growth, but the effect of higher AAs on early bone growth has to be further investigated. LLL is the anthropometric parameter that best correlates to bone status in the first month of life.
Larger prospective randomized trials, including neurologic follow-up, are warranted to verify the potential impact on longterm growth and body composition.
